EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gellan gum formulations containing natural polyphenolic compounds to treat oral candidiasis

Narchonai Ganesan iD, Lewis Oscar Felix iD, Biswajit Mishra, Liyang Zhang, Charilaos Dellis iD, Fadi Shehadeh, Danielle Wu, Lissette A Cruz, R M Arce, Eleftherios Mylonakis iD

Microbiology Spectrum · 02.09.2025 · 13 (9)

DOI: 10.1128/spectrum.00798-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 02.09.2025. Verfasst von Narchonai Ganesan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: Candidiasis, Oral, Candida albicans, Antifungal Agents, Polysaccharides, Bacterial. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral candidiasis (OC) is caused by Candida albicans , targeting immunocompromised individuals and developing drug resistance, highlighting the need for advanced therapeutics. Polyphenols such as caffeic acid phenethyl ester (CAPE) and ellagic acid (EA) display antifungal and immune-modulating properties. Incorporating CAPE and EA in gellan gum (GG) formulation enhances their applicability and effectiveness against OC. We developed GG-based formulations loaded with CAPE (1,000 µg/mL), EA (1,000 µg/mL), or CAPE + EA (1,000 µg/mL each) against C. albicans . GG formulations containing gellan (0.6% and 1.0%), genipin (5 mM), polyethylene glycol 400 (0.5%), and sorbitan monooleate 80 (0.5%) demonstrated enhanced release of CAPE and EA. The 0.6% GG formulation reduced C. albicans CFU by 2–6 log 10 within 30 min ( P < 0.05) and biofilm mass by 48% (CAPE, P = 0.0034), 60.7% (EA, P = 0.0980), and 70% (CAPE + EA, P = 0.0181). Both 0.6% and 1.0% GG formulations inhibited hyphae ( P < 0.0001). GG formulations showed high viability of human red blood cells (92%–94%) and human gingival cells (61%–69%). In artificial chewing simulations (ACS), 0.6% GG exhibited 67.7% (30 min), 55.9% (60 min), and 35.8% (120 min) for CAPE release, and 48.2% (30 min), 45.1% (60 min), and 42.1% (120 min) for EA. In 1% GG, about 44.07% (30 min), 43.8% (60 min), and 29.5% (120 min) of CAPE and 55.8% (30 min), 49.6% (60 min), and 50.6% (120 min) of EA were released. The present study is the first to evaluate the efficacy of CAPE- and EA-loaded GG formulations against C. albicans under ACS, thereby supporting their potential development for OC treatment. IMPORTANCE Candida albicans causes OC and presents challenges due to rising antifungal resistance and recurrence in immunocompromised patients. Existing antifungal treatments for OC often fail due to limited bioavailability, short retention times, adverse side effects, and the bitter taste of formulations, impacting patient adherence. CAPE and EA are recognized for their antifungal and immunomodulatory properties but face practical limitations in therapeutic applications, such as poor bioavailability and stability. The present study addresses these challenges by developing GG-based formulations incorporating CAPE and EA. The formulation exhibited significant antifungal efficacy against C. albicans biofilms and hyphal formation, reducing fungal viability under simulated mechanical chewing conditions. These GG-based systems showed minimal cytotoxicity, indicating promising biocompatibility and suitability for oral application. Therefore, the study presents the first report of CAPE/EA-loaded GG formulations under simulated chewing that highlights the importance of innovative therapeutic strategies to improve clinical outcomes in OC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Candidiasis, OralCandida albicansAntifungal AgentsPolysaccharides, BacterialPolyphenolsHumansBiofilmsMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Candida albicansartificial chewing simulationbiofilmcaffeic acid phenethyl esterellagic acidhyphae

Substanzen

gellan gumAntifungal AgentsPolysaccharides, BacterialPolyphenols

Autor:innen und Institutionen

  • Department of Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas, USA.
  • Department of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimioupolis Zografou, Athens, Greece.
  • Department of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece.
  • Department of Diagnostic and Biomedical Sciences, The University of Texas Health Science Center at Houston School of Dentistry, Houston, Texas, USA.
  • Department of Bioengineering, Rice University, Houston, Texas, USA.
  • Center for Craniofacial Research Instrumentation Core, The University of Texas Health Science Center at Houston School of Dentistry, Houston, Texas, USA.

ORCID-Profile: Narchonai Ganesan, Lewis Oscar Felix, Charilaos Dellis, Eleftherios Mylonakis

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Ganesan, N., Felix, L. O., Mishra, B., Zhang, L., Dellis, C., Shehadeh, F., Wu, D., Cruz, L. A., Arce, R. M., & Mylonakis, E. (2025). Gellan gum formulations containing natural polyphenolic compounds to treat oral candidiasis. Microbiology Spectrum, 13(9). https://doi.org/10.1128/spectrum.00798-25

Vancouver

Ganesan N, Felix LO, Mishra B, Zhang L, Dellis C, Shehadeh F, et al. Gellan gum formulations containing natural polyphenolic compounds to treat oral candidiasis. Microbiology Spectrum. 2025;13(9). doi:10.1128/spectrum.00798-25

BibTeX
@article{Ganesan2025,
  author = {Ganesan, Narchonai and Felix, Lewis Oscar and Mishra, Biswajit and Zhang, Liyang and Dellis, Charilaos and Shehadeh, Fadi and Wu, Danielle and Cruz, Lissette A and Arce, R M and Mylonakis, Eleftherios},
  title = {Gellan gum formulations containing natural polyphenolic compounds to treat oral candidiasis},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {9},
  doi = {10.1128/spectrum.00798-25}
}
Kostenlos starten →